<scp>CT</scp> ‐ <scp>P39</scp> Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study
CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study
Clive Grattan, Borislava Krusheva, Yevgeniya Dytyatkovska, Grażyna Pulka et al.
Citations
21 citations
Journal
Allergy
Topics
Urticaria and Related Conditions
Field-Weighted Citation Impact (FWCI)
35.03
article
CT ‐ P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study
Clive Grattan, Borislava Krusheva, Yevgeniya Dytyatkovska, Grażyna Pulka, Adam Reich, Ewa Springer, Sarbjit S. Saini, Marta Chełmińska, Marcus Maurer, Sung-Hyun Kim, Jong‐Ho Kim, Sewon Lee, Su‐Young Kim, Chun Wook Park, Keumyoung Ahn, Jochheim Ka, Maria Ratkova
article en
21 citations
Abstract
No abstract available for this paper.
Publication Tag
AllergyVol. 80(8)
Institutions
Guy's Hospital (GB), Medical University of Sofia (BG), Humboldt-Universität zu Berlin (DE), Hallym University Kangnam Sacred Heart Hospital (KR), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), Centrum Medyczne iMed24 (PL), Institute of Oriental Manuscripts (RU), Celltrion (South Korea) (KR), All-Med (PL), Gdańsk Medical University (PL), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), University of Rzeszów (PL)